liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
De novo design of a biologically active amyloid
VIB Switch Lab, Belgium; Katholieke University of Leuven, Belgium.
VIB Switch Lab, Belgium; Katholieke University of Leuven, Belgium.
VIB Switch Lab, Belgium; Katholieke University of Leuven, Belgium.
VIB Switch Lab, Belgium; Katholieke University of Leuven, Belgium.
Visa övriga samt affilieringar
2016 (Engelska)Ingår i: Science, ISSN 0036-8075, E-ISSN 1095-9203, Vol. 354, nr 6313, s. 720-+Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Most human proteins possess amyloidogenic segments, but only about 30 are associated with amyloid-associated pathologies, and it remains unclear what determines amyloid toxicity. We designed vascin, a synthetic amyloid peptide, based on an amyloidogenic fragment of vascular endothelial growth factor receptor 2 (VEGFR2), a protein that is not associated to amyloidosis. Vascin recapitulates key biophysical and biochemical characteristics of natural amyloids, penetrates cells, and seeds the aggregation of VEGFR2 through direct interaction. We found that amyloid toxicity is observed only in cells that both express VEGFR2 and are dependent on VEGFR2 activity for survival. Thus, amyloid toxicity here appears to be both protein-specific and conditional-determined by VEGFR2 loss of function in a biological context in which target protein function is essential.

Ort, förlag, år, upplaga, sidor
AMER ASSOC ADVANCEMENT SCIENCE , 2016. Vol. 354, nr 6313, s. 720-+
Nationell ämneskategori
Medicinsk bioteknologi (med inriktning mot cellbiologi (inklusive stamcellsbiologi), molekylärbiologi, mikrobiologi, biokemi eller biofarmaci)
Identifikatorer
URN: urn:nbn:se:liu:diva-132985DOI: 10.1126/science.aah4949ISI: 000387326300028PubMedID: 27846578OAI: oai:DiVA.org:liu-132985DiVA, id: diva2:1054744
Anmärkning

Funding Agencies|European Research Council (ERC) under the European Union, ERC [647458]; VIB; Industrial Research Funds of KU Leuven (IOF); Funds for Scientific Research Flanders (FWO); Flanders Institute for Science and Technology (IWT); Federal Office for Scientific Affairs of Belgium (Belspo) [IUAP P7/16]; FWO; KU Leuven [PF/10/014]; Wellcome Trust Institutional Strategic Support Fund (ISSF) [015615/Z/14/Z]; Biotechnology and Biological Sciences Research Council through its Research Equipment Initiative scheme [BB/E012558/1]; Goran Gustafsson Foundation; Swedish Research Council; Swedish Alzheimer Foundation; Flemish government; AXA Research grant; Marie Sklodowska-Curie Individual Fellowship under the European Union [H2020-MSCA-IF-2014-ST]; KU Leuven Stem Cell Programme

Tillgänglig från: 2016-12-09 Skapad: 2016-12-07 Senast uppdaterad: 2019-11-08

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Sök vidare i DiVA

Av författaren/redaktören
Nyström, SofieHammarström, PerNilsson, Peter
Av organisationen
KemiTekniska fakulteten
I samma tidskrift
Science
Medicinsk bioteknologi (med inriktning mot cellbiologi (inklusive stamcellsbiologi), molekylärbiologi, mikrobiologi, biokemi eller biofarmaci)

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 132 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf